OsteoarthritisEAR2KNEENCT07755579
Effect of Autologous Ear Cartilage Micrografting in Knee Osteoarthritis
A study testing Mytocel MSK - Autologous Ear Cartilage Micrografting in people with Osteoarthritis and Osteoarthritis (OA) of the Knee, run by Regenera Activa Worldwide S.L. at 1 site in Hungary.
Trial summary
The goal of this clinical trial is to learn if a single injection of autologous cartilage micrografts suspension, obtained through processing with a specialized technology patient's own small piece of ear cartilage, can improve knee osteoarthritis in adult men and women aged 18-75 with confirmed moderate knee… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Osteoarthritis, Osteoarthritis (OA) of the Knee, Moderate Osteoarthritis
- What is being tested?
- Mytocel MSK - Autologous Ear Cartilage Micrografting
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 33 participants
- Where
- 1 siteHungary
- Study dates
- 22 May 2023to 21 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed knee OA L-K grade II-III
- Symptomatic knee OA (with pain)
- Reduced mobility
Who cannot join
- Knee OA L-K grade IV
- Systemic Joint Disease (e.g. rheumatoid arthritis)
- Active autoimmune disease
- Active Oncologic process
- If other orthobiologic treatments administered in the last 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Autologous Cartilage Micrografting in Knee Cartilage Disease
The goal of this clinical trial is to learn if a single injection of autologous cartilage micrografts suspension, obtained through processing with a specialized technology patient's own small piece of ear cartilage, can improve knee osteoarthritis in adult men and women aged 18-75 with confirmed moderate knee osteoarthritis. The main questions it aims to answer are:
- Does a single intra-articular injection of autologous ear-cartilage micrografts improve patients' clinical symptoms and knee function over 12 months?
- What percentage of patients experience improvement in their complaints following treatment?
- Do MRI scans show measurable improvement in knee cartilage condition 6 months after treatment?
- Do inflammatory cytokine levels (IL-1β, IL-1α, IL-6, TNF-α) in joint fluid and cartilage tissue correlate with treatment response?
Read the detailed description
Background and Rationale Knee osteoarthritis is among the most common orthopedic conditions, affecting an estimated 10-12% of the population. Left untreated, it tends to progress, leading to worsening degenerative joint changes and functional loss. Treatment remains difficult because articular cartilage has very limited natural regenerative capacity. Currently used approaches - arthroscopic debridement, radiofrequency chondroplasty, and hyaluronic acid injection - have inconsistent or unsatisfactory efficacy.
This study reproduces a previously published treatment procedure using autologous cartilage micrografts sourced from the patient's own auricular (ear) cartilage, rather than from the knee joint itself or from cultured chondrocytes. Ear cartilage was selected as the donor tissue for three reasons: (1) elastic auricular cartilage has physical and biological properties closer to the hyaline cartilage found in the knee joint than other readily accessible cartilage sources; (2) the sampling procedure is simple and minimally invasive compared to harvesting from a weight-bearing joint; and (3) the perichondrial tissue surrounding ear cartilage contains a high density of chondroprogenitor cells responsible for regenerative processes.
Study Design The research has two components conducted on the same patient cohort: a clinical component evaluating the treatment's effect on patients' symptoms and joint imaging, and a laboratory component measuring inflammatory cytokine concentrations in tissue and joint fluid samples collected during the same procedure. This is a single-arm interventional study; there is no placebo or active comparator, and no randomization or blinding, since every enrolled participant receives the identical intervention on one knee affected by osteoarthritis.
Procedure
Each participant is treated on a single, affected knee. The procedure begins with drainage and storage of synovial fluid from the affected knee, for two reasons: synovial fluid in patients with knee osteoarthritis is expected to carry a high concentration of inflammatory cytokines that may impede improvement or contribute to discomfort, and removing it prevents dilution of the cartilage micrograft suspension subsequently injected.
Cartilage tissue is then harvested from the patient's own ear using a 2,5 mm dermatological punch - 3 biopsies maintaining a sterile field, under local anesthesia with lidocaine to ensure the harvesting is painless. The biopsies are placed inside a sterile medical disposable device class IIa (Rigeneracons RS) and 4 milliliters of sterile physiological saline are added to the harvested tissue. The device mechanically mills the cartilage into 80 microns micrografts thanks to Rigenera Technology - Mytocel MSK. This suspension is drawn into a syringe and delivered via a single anterolateral-approach injection directly into the synovial space of the osteoarthritic knee. The full procedure takes approximately 30 minutes and is considered as minimally invasive.
Cytokine Sub-Study For the laboratory component, a small aliquot (100 microliters) of the harvested ear cartilage suspension is frozen and stored (initially at -20°C, then at -80°C) at the time of tissue collection, before the remainder is injected. The synovial fluid drained from the knee prior to injection is handled and stored the same way. Concentrations of four cytokines associated with inflammation - IL-1β, IL-1α, IL-6, and TNF-α - are measured in both sample types. These measurements generate an individual inflammatory profile for each participant at baseline, which is then considered when interpreting each patient's clinical outcomes, on the hypothesis that a patient's baseline inflammatory state may influence how well they respond to treatment.
Basis for Expected Results A prior study using the same procedure and the same medical device reported successful interventions in all cases, with no wound-healing disorder or infection, no aesthetic deficit at the ear donor site, universal patient-reported pain relief and return to daily activity, significant improvement on clinical questionnaires, and an increase in lateral femoral condyle thickness on MRI performed at three years post-intervention. This study is designed to evaluate whether comparable outcomes are observed in the current knee osteoarthritis patient cohort.
Data Handling Data collection and processing are conducted solely for research purposes. Samples are processed anonymously using a code number system. A single technical record is maintained per participant, documenting all data, facts, and events relevant to or potentially influencing the study outcome. Code sheets linking code numbers to personal identifying data are kept in a locked file and separated from experimental data. Data are handled confidentially and are not shared with third parties. After processing, participant data are aggregated so that individuals cannot be identified from published results.
Statistical Analysis Outcome measures (KOOS subscales, including Pain and Symptoms/Stiffness; and Visual Analog Scale pain scores for current, worst, and best pain) were analyzed using repeated-measures ANOVA across five assessment timepoints (Baseline, Week 1, Month 3, Month 6, and Year 1) to test for an overall effect of visit/time. Mauchly's test of sphericity was applied to each outcome; where sphericity was violated, the Greenhouse-Geisser correction was used to adjust the degrees of freedom and significance values.
Where the overall visit effect was significant, simple contrasts compared each follow-up timepoint (Week 1, Month 3, Month 6, Year 1) against Baseline, with effect sizes reported as Cohen's d for each pairwise comparison. Descriptive statistics (mean, standard deviation, standard error, coefficient of variation) were reported for each timepoint.
- Being tested
- Mytocel MSK - Autologous Ear Cartilage Micrografting
- Keywords
- ear to knee, mytocel, mytocel msk, autologous micrografting, osteoarthritis, rigenera technology
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mytocel MSK - Autologous Ear Cartilage MicrograftingDevice
Also called Mytocel MSK, Autologous Micrografting, Rigenera Technology
Autologous Ear Cartilage micrografting using Rigenera Technology - Mytocel MSK. A 2.5 mm punch biopsy of the patient's own auricular ear cartilage is harvested under local anesthesia. The tissue is mechanically disaggregated within the device after addition of 4mL sterile physiological saline, yielding a micrograft suspension containing autologous cartilage progenitor cells - without cell culture, expansion, or enzymatic digestion. The micrograft suspension is then delivered as a single intra-articular injection. The procedure is performed once per patient, on one knee, in a single outpatient session lasting approximately 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Other | Autologous Cartilage Micrografting is performed to all subjects with moderate knee osteoarthritis Receives: Device: Mytocel MSK - Autologous Ear Cartilage Micrografting |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Knee Osteoarthritis Outcome Score (KOOS)
Change from baseline in KOOS subscale scores (including Pain and Symptoms/Stiffness), scored 0-100 with higher scores indicating better knee-related quality of life and function. Assessed via repeated-measures analysis across follow-up visits relative to baseline
Measured: Baseline, 1 week, 3 months, 6 months, 12 months, and 24 months
Secondary outcomes (2)
Change in knee cartilage thickness on MRI
MRI-assessed change in knee joint cartilage structure (e.g., lateral femoral condyle thickness) following treatment.
Measured: Baseline, 6 months
Baseline synovial fluid and cartilage tissue cytokine concentrations
Concentrations of IL-1β, IL-1α, IL-6, and TNF-α measured in synovial fluid and harvested ear cartilage tissue, used to generate an inflammatory profile for each participant at baseline.
Measured: Time of the procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2026
- Study start22 May 2023
- Primary completion21 Dec 2025
- Study completion21 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A disposable medical device used in regenerative medicine based treatment protocols
- Masking
- None (open label)
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- Regenera Activa Worldwide S.L.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Orthosera Kft., Semmelweis University
- Responsible party
- Sponsor
- Investigators
- Zsombor Lacza, Dr, Principal investigator, Prof. of Sports Science at University of Sports Science, Budapest, Hungary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07755579
- Sponsor's protocol ID
- MYTOCEL-KNEE-OA-052023
- Other IDs
- Official Research Registration, ref. BM/1298-3/2024, OGYÉI/67359-9/2023
- Acronym
- EAR2KNEE
- Status last verified
- Aug 2026
- First submitted
- 4 Aug 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Autologous Cartilage Micrografting in Knee Cartilage Disease
- ClinicalTrials.gov ID
- NCT07755579
- Acronym / sponsor ID
- EAR2KNEE / MYTOCEL-KNEE-OA-052023
- Keywords
- ear to knee, mytocel, mytocel msk, autologous micrografting, osteoarthritis, rigenera technology
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 33 participants (actual)
- Lead sponsor
- Regenera Activa Worldwide S.L.Industry (pharma, biotech, devices)
- Collaborators
- Orthosera Kft., Semmelweis University
- Study start
- 22 May 2023 (actual)
- Primary completion
- 21 Dec 2025 (actual)
- Study completion
- 21 Dec 2027 (estimated)
- First posted
- 10 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a single injection of autologous cartilage micrografts suspension, obtained through processing with a specialized technology patient's own small piece of ear cartilage, can improve knee osteoarthritis in adult men and women aged 18-75 with confirmed moderate knee osteoarthritis. The main questions it aims to answer are:
- Does a single intra-articular injection of autologous ear-cartilage micrografts improve patients' clinical symptoms and knee function over 12 months?
- What percentage of patients experience improvement in their complaints following treatment?
- Do MRI scans show measurable improvement in knee cartilage condition 6 months after treatment?
- Do inflammatory cytokine levels (IL-1β, IL-1α, IL-6, TNF-α) in joint fluid and cartilage tissue correlate with treatment response?
Detailed description
Background and Rationale Knee osteoarthritis is among the most common orthopedic conditions, affecting an estimated 10-12% of the population. Left untreated, it tends to progress, leading to worsening degenerative joint changes and functional loss. Treatment remains difficult because articular cartilage has very limited natural regenerative capacity. Currently used approaches - arthroscopic debridement, radiofrequency chondroplasty, and hyaluronic acid injection - have inconsistent or unsatisfactory efficacy.
This study reproduces a previously published treatment procedure using autologous cartilage micrografts sourced from the patient's own auricular (ear) cartilage, rather than from the knee joint itself or from cultured chondrocytes. Ear cartilage was selected as the donor tissue for three reasons: (1) elastic auricular cartilage has physical and biological properties closer to the hyaline cartilage found in the knee joint than other readily accessible cartilage sources; (2) the sampling procedure is simple and minimally invasive compared to harvesting from a weight-bearing joint; and (3) the perichondrial tissue surrounding ear cartilage contains a high density of chondroprogenitor cells responsible for regenerative processes.
Study Design The research has two components conducted on the same patient cohort: a clinical component evaluating the treatment's effect on patients' symptoms and joint imaging, and a laboratory component measuring inflammatory cytokine concentrations in tissue and joint fluid samples collected during the same procedure. This is a single-arm interventional study; there is no placebo or active comparator, and no randomization or blinding, since every enrolled participant receives the identical intervention on one knee affected by osteoarthritis.
Procedure
Each participant is treated on a single, affected knee. The procedure begins with drainage and storage of synovial fluid from the affected knee, for two reasons: synovial fluid in patients with knee osteoarthritis is expected to carry a high concentration of inflammatory cytokines that may impede improvement or contribute to discomfort, and removing it prevents dilution of the cartilage micrograft suspension subsequently injected.
Cartilage tissue is then harvested from the patient's own ear using a 2,5 mm dermatological punch - 3 biopsies maintaining a sterile field, under local anesthesia with lidocaine to ensure the harvesting is painless. The biopsies are placed inside a sterile medical disposable device class IIa (Rigeneracons RS) and 4 milliliters of sterile physiological saline are added to the harvested tissue. The device mechanically mills the cartilage into 80 microns micrografts thanks to Rigenera Technology - Mytocel MSK. This suspension is drawn into a syringe and delivered via a single anterolateral-approach injection directly into the synovial space of the osteoarthritic knee. The full procedure takes approximately 30 minutes and is considered as minimally invasive.
Cytokine Sub-Study For the laboratory component, a small aliquot (100 microliters) of the harvested ear cartilage suspension is frozen and stored (initially at -20°C, then at -80°C) at the time of tissue collection, before the remainder is injected. The synovial fluid drained from the knee prior to injection is handled and stored the same way. Concentrations of four cytokines associated with inflammation - IL-1β, IL-1α, IL-6, and TNF-α - are measured in both sample types. These measurements generate an individual inflammatory profile for each participant at baseline, which is then considered when interpreting each patient's clinical outcomes, on the hypothesis that a patient's baseline inflammatory state may influence how well they respond to treatment.
Basis for Expected Results A prior study using the same procedure and the same medical device reported successful interventions in all cases, with no wound-healing disorder or infection, no aesthetic deficit at the ear donor site, universal patient-reported pain relief and return to daily activity, significant improvement on clinical questionnaires, and an increase in lateral femoral condyle thickness on MRI performed at three years post-intervention. This study is designed to evaluate whether comparable outcomes are observed in the current knee osteoarthritis patient cohort.
Data Handling Data collection and processing are conducted solely for research purposes. Samples are processed anonymously using a code number system. A single technical record is maintained per participant, documenting all data, facts, and events relevant to or potentially influencing the study outcome. Code sheets linking code numbers to personal identifying data are kept in a locked file and separated from experimental data. Data are handled confidentially and are not shared with third parties. After processing, participant data are aggregated so that individuals cannot be identified from published results.
Statistical Analysis Outcome measures (KOOS subscales, including Pain and Symptoms/Stiffness; and Visual Analog Scale pain scores for current, worst, and best pain) were analyzed using repeated-measures ANOVA across five assessment timepoints (Baseline, Week 1, Month 3, Month 6, and Year 1) to test for an overall effect of visit/time. Mauchly's test of sphericity was applied to each outcome; where sphericity was violated, the Greenhouse-Geisser correction was used to adjust the degrees of freedom and significance values.
Where the overall visit effect was significant, simple contrasts compared each follow-up timepoint (Week 1, Month 3, Month 6, Year 1) against Baseline, with effect sizes reported as Cohen's d for each pairwise comparison. Descriptive statistics (mean, standard deviation, standard error, coefficient of variation) were reported for each timepoint.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A disposable medical device used in regenerative medicine based treatment protocols
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Other | Device: Mytocel MSK - Autologous Ear Cartilage MicrograftingAutologous Cartilage Micrografting is performed to all subjects with moderate knee osteoarthritis |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosed knee OA L-K grade II-III
- Symptomatic knee OA (with pain)
- Reduced mobility
Key exclusion criteria (5 listed)
- Knee OA L-K grade IV
- Systemic Joint Disease (e.g. rheumatoid arthritis)
- Active autoimmune disease
- Active Oncologic process
- If other orthobiologic treatments administered in the last 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mytocel MSK - Autologous Ear Cartilage MicrograftingAlso: Mytocel MSK, Autologous Micrografting, Rigenera TechnologyAutologous Ear Cartilage micrografting using Rigenera Technology - Mytocel MSK. A 2.5 mm punch biopsy of the patient's own auricular ear cartilage is harvested under local anesthesia. The tissue is mechanically disaggregated within the device after addition of 4mL sterile physiological saline, yielding a micrograft suspension containing autologous cartilage progenitor cells - without cell culture, expansion, or enzymatic digestion. The micrograft suspension is then delivered as a single intra-articular injection. The procedure is performed once per patient, on one knee, in a single outpatient session lasting approximately 30 minutes. | Device | Intervention Group |
Primary outcome
Change in Knee Osteoarthritis Outcome Score (KOOS)
Time frame: Baseline, 1 week, 3 months, 6 months, 12 months, and 24 months
Change from baseline in KOOS subscale scores (including Pain and Symptoms/Stiffness), scored 0-100 with higher scores indicating better knee-related quality of life and function. Assessed via repeated-measures analysis across follow-up visits relative to baseline
2 secondary outcomes
Change in knee cartilage thickness on MRI
Time frame: Baseline, 6 months
Baseline synovial fluid and cartilage tissue cytokine concentrations
Time frame: Time of the procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zsombor Lacza, Dr principal investigator
Prof. of Sports Science at University of Sports Science, Budapest, Hungary
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mytocel MSK - Autologous Ear Cartilage Micrografting in people with Osteoarthritis and Osteoarthritis (OA) of the Knee, run by Regenera Activa Worldwide S.L. at 1 site in Hungary.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Knee Osteoarthritis Outcome Score (KOOS) (time frame: Baseline, 1 week, 3 months, 6 months, 12 months, and 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.